Abstract
The effects of the angiotensin-converting enzyme lisinopril were compared with those of the calcium antagonist nifedipine in 162 non-insulin-dependent diabetic hypertensive patients for a 24-week period. In 83 and 79 patients, respectively, lisinopril and slow-release nifedipine produced similar reductions in blood pressure (systolic/diastolic: −16/−13 mmHg supine and −14/−11 mmHg standing after lisinopril; −15/−12 mmHg supine and −14/−11 mmHg standing after nifedipine). Fasting and post-prandial plasma glucose, glycosylated haemoglobin and plasma lipids appeared to be unaffected by either agent. Also, 28% of the patients on lisinopril and 30% of those on nifedipine presented microalbuminuria. Both drugs induced a reduction in the albumin excretion rate (AER). The geometric meanxx: tolerance factor of the reduction in AER among the 23 microalbuminuric patients on lisinopril (−10.0xx:1.3 μg/min) was greater, though not significantly so, than that observed in the 26 on nifedipine (−0.9x:1.2 μg/min). Moreover, lisinopril appeared to be better tolerated than nifedipine in our study population. Microalbuminuria is an important risk factor for cardiovascular mortality in non-insulin-dependent diabetic patients as well as in the general population. To what extent a reduction in the AER could ameliorate the cardiovascular prognosis in non-insulin-dependent diabetic patients is, at present, unknown. Finally, both lisinopril and nifedipine showed a similar antihypertensive effect in these patients which was not associated with significant differences in plasma glucose, insulin or lipid concentrations. The clinical consequences of the insignificant differences in AER remain unclear.
Similar content being viewed by others
References
Houston MC, Treatment of hypertension in diabetes mellitus. Am Heart J 118:819–829, 1989
Tuck M, Management of hypertension in the patient with diabetes mellitus. Focus on the use of angiotensin-converting enzyme inhibitors. Am J Hypertens 1:384s-388s, 1988
Simonson DC, Insulin sensitivity and the effects of antihypertensive agents: implications for the treatment of hypertension in patients with diabetes mellitus. Postgrad Med J 64 (Suppl 3):39–49, 1988
Hedner T, Samuelsson O, Lindholm L, Effects of hypertensive therapy on glucose tolerance: focus on calcium antagonists. J Intern Med (Suppl 735):101–111, 1991
Brichard SM, Santoni JP, Thomas JR, Van De Voorde K, Ketelslegers JM, Lambert AE, Long term reduction of microalbuminuria after 1 year of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated hypertensive patients. Diabete Metabol 16:30–36, 1989
Sorkin EM, Clissold SP, Brogden RN, Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapy efficacy in ischemic heart disease, hypertension and related cardiovascular disorders. Drugs 30:182–274, 1985
Kostis JB, Angiotensin converting enzyme inhibitors. 1.Pharmacology. Am Heart J 116:1580–1591, 1988
Dunn PJ, Cole RE, Soeldner JS, Further development and automation of a high pressure liquid chromatography method for the determination of glycosylated haemoglobins. Metabolism 28:777–779, 1975
Care RN, Feldbruegger D, Westgard J, Evaluation of the adaptation of the glucose peroxide 3-methyl-2-benzothiazolinone hydrazone-N-N dimethyline procedure to the technicon “SMA” 12/60 and comparison with other automated methods of glucose. Clin Chem 20:595–602, 1974
Heding LG, Radioimmunological determination of human C peptide in serum. Diabetologia 11: 541–548, 1975
Wahlefeld AW, Triglyceride determination after enzymatic hydrolysis. In: Bergemeyer HU (ed) Methoden der enzymatischen Analyse, 3rd edn, Vol 2. Verlag Chemie, Weinheim, pp 1878–1882, 1974
Burnstein M, Scholnick HR, Lipoprotein-polyanion-metal interactions. Adv Lipid Res 11:67–108, 1973
Scidel J, Schlumberger S, Klose J, Ziegenhorn F, Wahlefeld AW, Improved reagent for the enzymatic determination. J Clin Chem Biochem 19:838–844, 1981
Keen H, Chlouverakis G, An immunoassay method for urinary albumin low concentrations. Lancet 2:913–914, 1963
Jano T, Kawarmura T, Matsurmal H, Sasaki H, Nakayama M, Hara T, Matsuo S, Hotta N, Sakamoto N, Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 17:420–424, 1994
Bjorck S, Aurell M, Diabetes mellitus, the renin-angiotensin system, and angiotensin-converting enzyme inhibition. Nephron 55 (Suppl 1):10–20, 1990
Nielsen S, Schmitz A, Rehling M, Mogensen CE, Systolic blood pressure relates to the rate of decline of glomerular filtration rate in Type II diabetes mellitus. Diabetes Care 16:1427–1432, 1993
Fuller JH, Shipley MJ, Rose G, Jarret RJ, Keen H, Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. Br Med J 287:867–870, 1983
Christlieb AR, Warram JH, Krolewski AS, Busick EJ, Ganda OP, Asmal AC, Soeldner JS, Bradley RF, Hypertension: the major risk factor in juvenile onset insulin dependent diabetics. Diabetes 30 (Suppl 2):90–96, 1981
Knowler WC, Bennett PH, Ballantine EJ, Increased incidence of retinopathy in diabetics with elevated blood pressure. N Engl J Med 302:645–650, 1980
Collins R, Peto R, MacMaron S, hebert P, Fieback N, Eberlein K, Godwin J, Qizibbash N, Taylor J, Hennekens CH, Blood pressure, stroke and coronary heart disease. Part 2. Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827–838, 1990
O'Hare JP, Anderson JV, Miller ND, Bloom SR, Corral R JM, The relationship of the renin-angiotensin-aldosterone system to atrial natriuretic peptide and the natriuresis of volume expansion in diabetics with and without proteinuria. Postgrad Med J 64 (Suppl 3):35–38, 1988
Gall Ma, Nielsen FS, Smidt UM, Parving H-H, The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36:1071–1078, 1993
Tsalamandris C, Allen JJ, Gilbert RE, Sinha A, Panagiotopoulis S, Cooper ME, Jerums G, Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 43:649–656, 1994
Baba T, Murabayashi S, Takabe K, Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type II (non-insulin-dependent) diabetic patients with microalbuminuria: a randomized controlled trial. Diabetologia 32:40–44, 1989
Jerums G, Allen TJ, Tsalmandris C, Cooper ME forthe Melbourne Diabetic Nephropathy Study Group, Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. Kidney Int 41:904–911, 1992
Remuzzi G, Bertani T, Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384–394, 1990
Melbourne Diabetic Nephropathy Study Group, Comparison between perindoprial and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 302:210–216, 1991
Lacourciere Y, Nadeau A, Poirier L, Taucrede G, Captopril or conventional therapy in hypertensive Type I diabetics. Threeyear analysis. Hypertension 21:786–794, 1993
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M, Longterm stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type II diabetic patients. Ann Intern Med 118:577–581, 1993
Koffler M, Ramirez LC, Raskin P, The effects of many commonly used drugs on diabetic control. Diab Nutr Metab 2:75–93, 1989
Holdaas H, Hartmann A, Lien MG, Nilsen L, Fauchald P, Jervell J, Berg KJ, Contrasting effect of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 229:163–170, 1991
Mörlin C, Baglivo H, Boeijinga JK et al. Comparative trial of lisinopril and nifedipine in mild to essential hypertension. J Cardiovasc Pharmacol 9 (Suppl 3):S48-S52, 1987
Witchitz S, Serradimigni A, Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. J Hum Hypertens 3:29–33, 1989
Os I, Bratland B, Dahloef B, Gisholt K, Syvertsen JO, Tretil S, Lisinopril or nifedipine in essential hypertension? A Norwegian multicentre study on efficacy, tolerability and quality of life in 828 patients. J Hypertens 9:1097–1104, 1991
Schnack CH, Capek M, Banyai M, Kautzky-Willer A, Prager B, Schernthauer G, Long term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive Type I diabetic patients with microalbuminuria. Acta Diabetol 31:14–18, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Crepaldi, G., Carraro, A., Brocco, E. et al. Hypertension and non-insulin-dependent diabetes. Acta Diabetol 32, 203–208 (1995). https://doi.org/10.1007/BF00838494
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00838494